SNOMED CT Templates

Page tree

StatusReady for implementation
Version

1.0

Descriptions:

Termdescription typeLanguage/acceptabilityLanguage/acceptabilityCase significance
Product containing [substance] (medicinal product)FSNus:Pgb:Pci
[substance]-containing productSYNus:Pgb:Pci


Concept model:

Role group cardinalityAttribute cardinalityAttribute in role group cardinalityAttributeValue
0..01..1

116680003 |Is a (attribute)|

763158003 |Medicinal product (product)|

1..*
1..1

127489000 |Has active ingredient (attribute)|


<  105590001 |Substance (substance)|

Definition status:  

900000000000073002 |Defined|

Applies to:

<  763158003 |Medicinal product (product)|

Template Language


Rules for description generation:

  1. Apply General rules for generating descriptions for templates
  2. 'and [substance]' needs to be added for FSN for multiple |has active ingredient| and they are self-grouped, e.g. Product containing calcium carbonate and sodium bicarbonate (medicinal product)
  3. '[substance]- and' needs at the beginning of the description to be added for PT for multiple |has active ingredient| and they are self grouped, e.g. Calcium carbonate- and sodium bicarbonate-containing product
  4. For multiple ingredients, the ingredients in each description need to be in alphabetical order e.g. Codeine and paracetamol for FSN but Acetaminophen and codeine (for US PT).

JIRA ticket for implementation:

DRUGS-273 - Getting issue details... STATUS

INFRA-3023 - Getting issue details... STATUS

DRUGS-641 - Getting issue details... STATUS

INFRA-12576 - Getting issue details... STATUS

  • No labels

19 Comments

  1. Penni Hernandez

    Kai Kewley Not sure how to represent this in the template here, but the substances have a US/GB spelling list that would need to drive the terming.  I don't think it has been implemented yet, but is scheduled.  I'm including an example of "ethinyl estradiol" and "ethinylestradiol"

     

  2. Kai Kewley

    Hi Penni Hernandez, I have two questions.

    • Will the substances US/GB terms be added to the existing US/GB terms list in use in the authoring tool?
    • Could we make this the general behaviour? Should an alternate preferred term and additional synonyms always be added for all concepts when there are matching US/GB spellings and templates are being used?

    CC Yongsheng Gao

    1. Toni Morrison

      Kai Kewley Penni is on vacation today. I can answer the first question - yes, there will be a file submitted to add new US/GB drug names. I would expect these names to be applied to any SNOMED concept that uses the drug name.

      I'm not familiar enough with the template functionality to tell you anything further so that will need to wait for Penni's return.

  3. Nicola Ingram

    Hi Yongsheng Gao Can you review this Template for me, it is the first of several products templates.

    Toni has raised a question re theDefinition status. I checked 900000000000073002 |Defined (core metadata concept)| against Clinical finding/disorder templates and Procedure templates that are In PROD but in the Browser it is 900000000000073002 |Sufficiently defined by necessary conditions definition status (core metadata concept)|.

    Also I have added points 2 and 3 to 'Rules for description generation' for implementing US/GB variations and applying case sensitivity using substances as the source of truth.Can this be made to work?  

    There will also be a need for templates for 2, 3, and 4 substances because of adding 'and' between the terms e.g.Product containing [substance] and [substance] and [substance] (medicinal product)

  4. Yongsheng Gao

    Hi Nicola Ingram, We have updated the FSNs for both defined and primitive definition status. Just use ID with preferred term would be fine for template specification, e.g. 900000000000073002 |Defined|. The preferred terms are much easier to read.

    The descriptions are filled in by terms from substance hierarchy. The spelling and case significance values are used for construction of descriptions. The same approach are applicable for all other variables in the concept model and description slots, e.g. organisms for infection templates.  Therefore, we do not need to create specific description rules for substance. 

    Regarding multiple active ingredients, the template language does not support such specification yet. I had discussion with Linda in October. I will will raise ticket to enhance the template language to support our use cases. So, please create the template for single ingredient product first.

  5. Nicola Ingram

    Thanks Yongsheng Gao so will this account for US and GB spelling variations?

    1. Yongsheng Gao

      Yes, the new description should be a copy of the source term. Please note, we only create terms for FSN and PTs. The US and GB variations for PT would be created. The other synonyms are not covered.

      1. Toni Morrison

        Nicola Ingram Not sure what Yong's comment about "other synonyms" means - there are no synonyms allowed for the concepts in the Medicinal product Hierarchy. Assuming it was an oversight but if that is not the case, please advise so we can discuss. Thanks.

        1. Yongsheng Gao

          The process for generating FSNs and PTs will only take FSNs and PTs from the source values in concept model. So, we cannot generate new synonyms unless they are specified in the template. For example, different degrees of burn, CT procedures, they all have additional synonyms specified in the templates. This is the general approach for all templates including drugs. It should not be a problem for drugs because there won't be additional synonyms.

  6. Nicola Ingram

    Yongsheng Gao Toni Morrison We only need  FSN and PTs. The US and GB variations for PT are all that is required, and other synonyms are not permissible.


    Following meeting just now - Template placed in review for Yongsheng Gao

  7. Yongsheng Gao

    Nicola Ingram and Toni Morrison I have reviewed the template and it is ready for implementation. Please see the JIRA ticket  INFRA-3023 - Getting issue details... STATUS for progress by the technical team. Cheers, Yong

  8. Nicola Ingram

    Great! 

  9. Nicola Ingram

    Will add some concepts for testing to DRUGS-273 and TBBA-355

  10. Nicola Ingram

    The template has been updated to support multiple active ingredients. 

  11. Nicola Ingram

    Yongsheng Gao I have added Rule 4 above to the 4 product templates currently  in implementation or in review at the request of Toni to support alphabetical ordering of multiple ingredient products. Do you approve of this addition?

    1. Yongsheng Gao

      Nicola Ingram Thanks, that is a useful rule for consistent description convention. 

  12. Nicola Ingram

    Yongsheng Gao Template is ready for review prior to sending to the tech team for publication. Is the role group cardinality for 127489000 |Has active ingredient (attribute)| correct?

    1. Yongsheng Gao

      The cardinality of the role group is to support multiple active ingredients.  I have updated the template and let me know if any further change is needed.

  13. Nicola Ingram

    Thanks Yongsheng Gao no further changes required. The PT descriptions with hyphens are a complexity but I think we've covered that in the Rules for description generation.